support_agent

Your contact persons

CHEPLAPHARM Arzneimittel GmbH

View:
format_list_bulleted grid_view

10/25/2022

CHEPLAPHARM receives growth capital of €550 Million from two leading global investors
Archive
Read more chevron_right

08/29/2022

CHEPLAPHARM increases revenue and earnings in the first half of 2022
Archive
Read more chevron_right

06/01/2022

CHEPLAPHARM strengthens its oncology portfolio
Archive
Read more chevron_right

05/16/2022

CHEPLAPHARM acquires rights to CMV medicine
Archive
Read more chevron_right

04/29/2022

CHEPLAPHARM continues profitable growth track in 2021 as well
Archive
Read more chevron_right

03/21/2022

Significant and sustainable site expansion
Archive
Read more chevron_right

03/01/2022

CHEPLAPHARM acquires additional oncology drugs
Archive
Read more chevron_right

02/23/2022

Jens Rothstein hands over his CFO role to Kia Parssanedjad
Archive
Read more chevron_right

02/11/2022

CHEPLAPHARM announces successful pricing of Term Loan B
Investor Relations
Read more chevron_right

11/19/2021

CHEPLAPHARM continues strong Growth
Archive
Read more chevron_right
Back to top expand_less